NCT02406209

A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: Aldeyra Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis. Subjects will be randomized 1:1:1 to receive multiple doses of NS2 0.5%, NS2 0.5% and Pred Forte® 1%, or Pred Forte® 1%. Free aldehydes are thought to be related to inflammatory diseases such as uveitis. NS2, a small molecule aldehyde trap, may decrease inflammation by lowering aldehyde levels.

Conditions

• Non-infectious Anterior Uveitis

Interventions

Type	Name	Description
DRUG	NS2	NS2 ophthalmic drops (0.5%)
DRUG	Prednisolone acetate ophthalmic suspension (1%)

Timeline

• Start date: 2015-03-01
• Primary completion: 2016-04-01
• Completion: 2016-04-01
• First posted: 2015-04-02
• Last updated: 2023-03-27
• Results posted: 2023-03-27

Locations

15 sites across 1 country: United States